In conversation with John Cryan
Paraminder Dhillon and John F. Cryan
Abstract
John F. Cryan is Chair of the Department of Anatomy and Neuroscience, Principal Investigator in the APC Microbiome Ireland Institute and Vice President for Research and Innovation at University College of Cork, Ireland. He obtained his bachelor’s and doctoral degrees (in Biochemistry and Pharmacology, respectively) from the University of Galway and undertook postdoctoral research experience in the USA, at the University of Pennsylvania and The Scripps Research Institute. He was also a visiting fellow at the Department of Psychiatry, University of Melbourne, for a couple of years post-PhD. In 2002, John took up a position in industry as a laboratory head at the Novartis Institutes for BioMedical Research in Basel, Switzerland. After a 4-year stint at Novartis, he returned to academia in late 2005 as a Lecturer and then Senior Lecturer in Pharmacology at University College Cork (UCC). The Cryan lab now focuses on determining the impact of the gut microbiota on the human brain and behaviour, with a particular interest in the brain–gut–microbiome axis in the context of depression. John has published more than 600 peer-reviewed papers and has received many honours and accolades in recognition of his contributions to neuropharmacology and microbiome research, including the Datta lecture award from FEBS in 2022. In this interview, he outlines how he became interested in the role of the microbiome in brain development and disease, provides advice to budding scientists and highlights the broader public health implications of his research.
What are the main research themes that your lab is interested in?
I’m interested in understanding the relationship between the microbes in the gut and how they influence brain, behaviour and physiology, and trying to see if we can eventually translate these findings to humans.
Did you undergo your early training in neuroscience?
Originally, I trained as a biochemist, and then I moved into neuroscience and became interested in understanding the effects of stress on the brain and the body, relying on behaviour as a read-out. I quickly realised that there are many factors that can influence brain function within our bodies. This was back in the ‘90s, when there was a lot of interest in the new field of psychoneuroimmunology, which is basically looking at how the immune system affects the brain and behaviour. This stemmed from a growing understanding that peripheral factors can influence what’s going on in the human brain, and that immune dysregulation is a key feature of disorders such as depression. I worked on understanding human emotions using animal models for many years and then spent 4 years working in the industry at Novartis in Switzerland, as a group leader for behavioural pharmacology and neuroscience. I then decided to return to academia in Cork focusing on depression once again.
How did your shift from ‘pure’ neuroscience to exploring the role of gut microbiota in neurobiology come about?
After I returned to Cork, I realised that some of the models I used for depression were also used by others to model gut–brain dysfunction in disorders such as irritable bowel syndrome (IBS). IBS is an unloved disorder – very common, but people don’t like to talk about it – that involves alternations in bowel habits and abdominal pain. Nowadays, it is classified as a disorder of gut–brain interactions. We know that stress is one of the key exacerbators of IBS symptoms, as it is in depression, and that early-life stress and trauma give rise to an increased susceptibility to IBS as well as depression. After I joined UCC, I started collaborating with my clinical psychiatry colleague Ted Dinan – we combined our strengths to develop a truly translational programme of research. We started addressing the idea of comorbidity in the disorders we were studying, looking at relationships between mental illness and gastrointestinal illness. We learned that a lot of people with IBS also suffer from anxiety and depression. Maybe this is because they had trauma early on, or it might be related to genetic and epigenetic influences. So, we started modelling this in animals, and were particularly interested in an animal model of early-life stress called the maternal separation model (where rat pups are separated from their mums). We found that when these animals grow up, they have a whole-body syndrome where stress affects their immune system, gut barrier functions, brain and behaviour. In 2008, we published a study showing that stress also resulted in a long-term change in the compilation of microbes in the gut. This was a kind of ‘oh, there’s something here!’ moment; we thought it could be epiphenomenonal, could be something more. Siobhain O’Mahony, who’s now in a faculty position here, was a PhD student at the time. Siobhain was keen to look into this further with colleagues in microbiology and our response probably could have been more encouraging! But we started wondering whether, if stress affects microbes, microbes also affect stress? In Cork, we have access to a germ-free facility – these are animals that grow up without any microbes in their gut or elsewhere – and we looked at how these animals respond to stress. It turned out that they have an exaggerated stress response and their brains don’t function normally. This was in 2009–2010, and all of a sudden, I felt I’d been looking at stress in the wrong way.


